MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease_Anthrax
Altimmune, Inc. (NASDAQ: ALT)*
Organization & Developments: Atimmune
Parents
Altimmune, Inc. (NASDAQ: ALT)*
Children
*Altimmune is a clinical stage immunotherapeutic biotech company developing two cutting-edge vaccine delivery platforms, RespirVec and Densigen.
*Altimmune is currently designing and developing immunotherapeutic products envisioned to address a plethora of disease indications comprising of acute respiratory infections, chronic viral infections, and even cancer.
2018: Altimmune Reports Mixed Bag Of Updates_seekingalpha.com
2019: Altimmune Reports Positive NasoVax Data And Is Looking For Partners_seekingalpha.com
2020: Altimmune Is Off The Sidelines And Is Developing A Coronavirus Vaccine_seekingalpha.com
2020: Altimmune Launches Clinical Trial for COVID-19 Vaccine for the Treatment of Patients with Early SARS-CoV-2 infection_Biobuzz Directory
2020: Altimmune: Needs To Focus On NasoVAX
2020: Altimmune: On The Sidelines For Wuhan Coronavirus Crisis_seekingalpha.com
2020: Altimmune: Waiting For Their Next Move Against COVID-19
2021: Altimmune: Changing The Thesis
2021: Trying To Assess Altimmune
2022: Altimmune (ALT) Investor Presentation - Slideshow_seekingalpha.com
2022: Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD_altimmune
2022: Altimmune Appears To Have A Winner, But Will The Market Believe?_ seekingalpha.com
2022: Altimmune: Overreaction On NASH Data Creates Buying Opportunity_seekingalpha.com
2022: Altimmune: Weight Loss Data Signals A Costly Confusion_ seekingalpha.com
2022: Reassessing Altimmune_seekingalpha.com
2024: Altimmune 2025: Redefining Obesity And MASH Treatment_seekingalpha.com
2024: Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
2024: Altimmune Awaits Results Of Fatty Liver Disease Drug Pemvidutide
2024: Altimmune CEO on what’s next for its experimental obesity drug_ www.cnbc.com
2024: Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2024: Altimmune Could Find A Partner For Its Phase 3 Exercise_ seekingalpha.com
2024: Altimmune reports positive trial results for liver disease drug By Investing.com
2024: Altimmune Targets Obesity Market With Weight-Loss Drug That Preserves Lean Muscle Mass
2024: Altimmune touts 'best-in-class' lean mass results for weight loss therapy in quest to outdo big time competitors
2024: Altimmune, Inc. (ALT): A Bull Case Theory
2024: Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
2024: Altimmune: Emerging Position In Competitive Space, But Risks Remain_ seekingalpha.com
2024: Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge
2024: Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
2024: Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects_seekingalpha.com
2024: Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
2024: Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook
2024: Buy Altimmune's Potential Market Disruption With Pemvidutide
2024: Consider Buying Potential Takeover Target Altimmune
2024: Regulatory And Clinical Catalysts Ahead For Altimmune
2024: Thoroughly Derisked, Altimmune Is Now A Great Buy_ seekingalpha.com
2024: With 56% ownership, Altimmune, Inc. (NASDAQ:ALT) boasts of strong institutional backing
2025: Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway
2025: Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due In Q2
2025: Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
2025: Altimmune wins FDA fast track status for alcohol use disorder therapy
2025: Altimmune: Deciphering The MASH Crash (Rating Upgrade)
2025: Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)
2025: Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine
2025: Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity
2025: Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH_seekingalpha.com
2025: Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook
2026: Altimmune moving headquarters from Gaithersburg to New Jersey
Jumps
*Key People: Altimmune
Finance & Acquisitions: Altimmune